trending Market Intelligence /marketintelligence/en/news-insights/trending/nqidyzmy6asmdafxmhktya2 content esgSubNav
In This List

Amid probe, Chinese inspectors find no quality issues at 45 vaccine companies

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Amid probe, Chinese inspectors find no quality issues at 45 vaccine companies

China's State Drug Administration has found no quality or safety problems at 45 vaccine companies during inspections spurred by the discovery of serious irregularities at one vaccine maker, state-owned Xinhua News reported.

In July, a surprise inspection of Shenzhen-listed Changsheng Bio-Technology Co. Ltd. found serious irregularities, including the fabrication of production records in the manufacturing of rabies vaccines. Chinese President Xi Jinping ordered a thorough investigation into the matter, and the State Drug Administration launched inspections of other vaccine manufacturers in the country.

Xinhua, citing information posted on the State Drug Administration's website, reported Sept. 7 that 38 vaccine makers were found to be in compliance with good manufacturing practices and were meeting other rules and regulations. The remaining companies had halted vaccine production for more than three years and therefore were not selling products into the marketplace.

The vaccine safety inspections were conducted between July 23 and Aug. 9, Xinhua reported. During these checks, the inspectors thoroughly examined the companies' facilities and laboratory controls, materials, production and quality management.

The state agency plans to step up efforts on vaccine quality supervision to detect and remove safety hazards faster, Xinhua said. The regulator will also ensure that local drug authorities initiate routine supervision on vaccine manufacturers to ensure they abide by regulations.